Group items tagged

According to the National Health Services (NHS)'s new mandate, pharmaceutical companies seeking to participatign its Antimicrobial Product subscription model must certify to the BSI Kitemark for minimised risk of Antimicrobial Resistance (AMR) This move is part of the NHS's strategy to tackle the growing global threat of AMR by ensuring that antibiotic manufacturers adhere to stringent environmental controls. The NHS antibiotic subscription model is the first of its kind globally, offering pharmaceutical companies a fixed annual fee based on the value and availability of their antimicrobials to the NHS, rather than the quantity consumed. The innovative approach aims to stimulate the development of new antibiotics while addressing the environmental impact of their production. The NHS antibiotic subscription model is a ground-breaking incentive program as the first in the world to pay companies a fixed annual fee for antimicrobials based on the value of the drugs to the NHS, and their availability, instead of the volumes used.

How do providers feel about the importance of PHM? What will happen to PHM if Obamacare is repealed? Read on to learn about the attitudes toward population health and how it ties into value-based payments.

Medical billing services are more of a conundrum in present times because the process has gotten complicated with time. The government has set value-based criteria for the providers to follow, for ensuring a productive health system while cutting costs.

The NHS has launched plans to expand pioneering subscription-style drug contracts to develop lifesaving antibiotics of the future. It is building on its world-first pilot to incentivise the pharmaceutical industry to develop new antibiotics that could be offered to NHS patients when they need them the most. The consultation has launched almost a year to the day that contracts for two superbug-busting drugs were rolled out as part of a world-first pilot. Cefiderocol and ceftazidime-avibactam, new antibiotics manufactured by Shionogi and Pfizer respectively, were awarded world-first subscription contracts which provided the companies with a fixed annual fee based primarily on the availability of the drugs and their value to the NHS, as opposed to the volumes used. By breaking the link between the payments companies receive and the number of their antibiotics prescribed, the NHS is removing any incentive to overuse antibiotics, decreasing the risk of life-threatening infections, such as sepsis and pneumonia, becoming resistant to treatment.

The Pharmaceutical Services Negotiating Committee (PSNC) has refused to accept the Department of Health and Social Care (DHSC)'s decision to get rid of 'transitional payments' from February 2023. The pharmacy negotiator said that 'any reductions in payments at this point will be impossible for community pharmacy contractors to manage financially.' "We are also continuing to be clear with officials and ministers that CPCF funding needs an urgent uplift to help businesses to cope with soaring costs being driven by inflation and the workforce crisis. We put a comprehensive business case to the government for this uplift in the last CPCF negotiations." The latest 'transitional payments decision' by the Department follows the announcement last year that the value of the these payments would be phased down over the second half of 2022/23 and will be based on the latest monitoring and analysis of funding delivery. PSNC says it submitted a fully-costed bid for a 'Pharmacy First' service in its last round of negotiations alongside the case for an uplift to core CPCF funding. Both of these were refused.

Walgreens Boots Alliance, Boots UK's parent company, has appointed Tim Wentforth as its new CEO, effective on 23 October. He joined WBA at a pivotal time when the company plans to downsize the business while driving execution and creating greater value for employees, patients, customers and shareholders. Wentforth replaced Rosalind Brewer, who stepped down on 1 September, after two years at the helm. He joined from Evernorth, Cigna's health services organisation based in Connecticut, where he served as its founding CEO. Prior to Cigna, he also held top roles in companies including specialty pharmacy company Accredo and pharmacy benefit manager Express Scripts.

A recent report from Healthwatch England has highlighted that while people highly value the accessibility of community pharmacies, both in terms of location and prompt service, they also encounter challenges in getting the most out of their pharmacy care experience. The report titled 'Pharmacy: What People' is based on the research conducted by the organisation in November last year, involving 1,650 people who shared their experiences of pharmacy services in England. It showed the country's notable dependence on community pharmacies, with 72 per cent of respondents saying they have used a community pharmacy in the past three months. Usage of online pharmacies is considerably lower than community pharmacies, with only 18 per cent of individuals having used an online pharmacy in the past three months, according to the report published on Tuesday (30 April).

The National Pharmacy Association (NPA) has lashed out at the British Medical Association (BMA) after GP leaders voted in favour of the motion to terminate pharmacy blood pressure checks with immediate effect and redirect the funds into pharmacy dispensing fees. Commenting on the BMA's vote, NPA chair Nick Kaye said: "It benefits no-one, least of all patients, for one set of health care professionals to talk down the services provided by another." He emphasised the importance of investment and collaboration across the healthcare system, particularly between general practice and community pharmacies, to provide the best possible care for patients. Furthermore, Kaye stressed the value of pharmacy-based NHS clinical services in improving access to care, while also providing more convenient care for patients and relieving pressure on other parts of primary care. "It would be terribly shortsighted to row back on preventative services such as hypertension case finding, which will be cost-saving as well as lifesaving in the long term," he warned. He noted that the NHS will only meet the growing needs and expectations of the ageing population by making the most of capacity and skills across the whole system.

Community Pharmacy England (CPE) has submitted evidence to Lord Darzi's investigation into NHS performance, highlighting the sector's value, challenges, and potential opportunities. Professor Ara Darzi, Baron Darzi of Denham, is leading the investigation, which has been commissioned by the Secretary of State for Health and Social Care to examine the challenges facing the healthcare system ahead of the development of a new 10-year plan for health. The investigation's findings are expected to be published in September 2024. As the sector's representative body, CPE has provided evidence to ensure that the performance and challenges faced by community pharmacies are considered as part of his review. Their submission, based on internal analysis and independent reports, highlighted the severe funding crisis facing the sector, which is significantly impairing access to care for those most in need.

The Medicines and Healthcare products Regulatory Agency (MHRA) has awarded marketing authorisation to CStone Pharmaceuticals for sugemalimab (Eqjubi) as a first-line treatment for non-small cell lung cancer (NSCLC) in the UK. NSCLC is the most common form of lung cancer, accounting for around 80 to 85 out of 100 cases. Sugemalimab is now approved as a first-line treatment, in combination with platinum-based chemotherapy, for adult patients with metastatic NSCLC who do not have EGFR-sensitive mutations or ALK, ROS1, or RET genomic alterations. This UK approval follows its recent authorisation by the European Commission, marking the second international approval for sugemalimab. CStone's CEO Dr. Jason Yang described the UK's approval as a significant milestone in their global expansion strategy. "Sugemalimab is the first domestic anti-PD-L1 antibody to receive approval outside of China and has already entered the world's second-largest pharmaceutical market, the EU. "Now, with the UK approval, sugemalimab continued to expand its presence in the European market. The long-term survival data, recently presented at this year's ESMO Congress, further confirmed sugemalimab's value in the frontline treatment landscape for metastatic NSCLC," he said.

Currently, the healthcare system is going through a critical phase that involves shifting paradigms, from the volume-based model to the value-based reimbursement system. All of this is intended to minimize healthcare costs and raise the quality of care.

Ireland-based Perrigo Company has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global for $51m.

We see hospitals and practices, in general, are equipped with the latest certified EHR systems aiding a new-age healthcare system to evolve, sustain, and respond with improved outcomes. Medical billing services and the doctors have to follow HIPAA rules, and physicians must demonstrate meaningful use to avoid negative payment adjustments. All of this means we are transitioning to the value-based system moving towards improvement.

Since the healthcare industry has taken serious measures to revamp healthcare services, the emphasis on incentive payment programs has increased. MIPS and MACRA, and more offer facilities to physicians that regular payment method can never provide

Healthcare Solutions meets the challenges posed by Medicaid meaningful use program in a systematic and timely manner. It is noticed that many healthcare professionals are using healthcare IT consultants to collaborate and construct a plan to deal with technology addressing the value-based reimbursement system.

The medical profession is very noble if we look at it from a patient's perspective. If we look at it from a student's viewpoint, it requires a lot of hard work. However, we are here to discuss how medical professionals look at their jobs and what keeps their clock ticking! Why they do what they do? I will share with you the reasons behind their everyday motivation.

If right now you outsource your revenue cycle management, you realize that the performance of your medical billing service provider is central to your medical practice's financial success. Repayment keeps on declining, and the movement towards value-based will keep on jeopardizing your medical revenues if your medical billing company is not working as expected.

Healthcare IT makes the use of technology for better outcomes. Such applications will facilitate the reimbursement process and providers in general. P3, as an MIPS consulting service, assimilates with technology to report on behalf of the providers and value-based care will only benefit from these technological marvels.

The healthcare industry is going to be evolving now more than ever in 2020. Physicians, medical billing companies, health IT leaders, clearinghouses, governing authorities, insurance companies, thus, everybody is up for quality care services.